Clinical trial
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable…
NCT00164892 · Chinese University of Hong Kong, Other · Unknown status
Key facts
| NCT number | NCT00164892 |
|---|---|
| Title | Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial |
| Official title | Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial |
| Lead sponsor | Chinese University of Hong Kong, Other |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer of Stomach |
| Intervention type | Drug |
| Interventions | Oral Vioxx (Rofecoxib) |
| Enrollment | 214 |
| Start date | Oct 1, 2004 |
| First posted | Sep 14, 2005 |
| Last update posted | Nov 17, 2005 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: